MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the...
February 27 2017 - 6:00PM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number:4875), today announced that Associate
Professor Kerrie McDonald, Head of the Cure Brain Cancer Foundation
Biomarkers and Translational Research Group at the Lowy Cancer
Research Centre, University of New South Wales, will present
positive results from an in vitro study that examined the potential
clinical efficacy of MN-166 (ibudilast) in combination with
temozolomide (TMZ) in patient-derived cell lines (PDCLs) and an
orthotopic glioblastoma (GBM) animal model study during the 5th
Quadrennial Meeting of the World Federation of Neuro-Oncology
Societies (WFNOS) to be held May 4-7, 2017 in Zurich, Switzerland.
The presentation, "Treatment of recurrent glioblastoma with the
cytokine inhibitor ibudilast in combination with temozolomide,"
which is scheduled for May 5, 2017, is expected to extend
understanding about the synergistic activity between MN-166
(ibudilast) and TMZ and the potential for MN-166 (ibudilast) to
improve treatment for GBM patients.
Based in part on these positive in-vitro and animal model study
results, MediciNova is preparing to initiate a Phase 2 trial for
the treatment of Grade IV Glioblastoma with Dr. Kerrie McDonald in
Australia.
About Glioblastoma
Malignant primary brain tumors represent the most frequent cause
of cancer death in children and young adults and account for more
deaths than melanoma. According to the American Association of
Neurological Surgeons, glioblastoma (GBM) is an aggressive,
extremely lethal form of brain malignancy that develops from glial
cells (astrocytes and oligodendrocytes) and rapidly grows and
commonly spreads into nearby brain tissue. GBM is classified as
Grade IV, the highest grade, in the World Health Organization (WHO)
brain tumor grading system. The American Brain Tumor
Association reports that GBM represents 15% of all brain tumors and
55% of all gliomas and has the highest number of cases of all
malignant tumors, with an estimated 12,390 new cases predicted for
2017. Despite decades of advancements in neuroimaging,
neurosurgery, chemotherapy, and radiation therapy, only modest
improvements have been achieved and the prognosis has not improved
for individuals diagnosed with GBM. Median survival is 14.6
months and only approximately 2% of GBM patients survive longer
than 36 months.
About MN-166 (ibudilast)
MN-166 (ibudilast) has been marketed in Japan and Korea since
1989 to treat post-stroke complications and bronchial asthma.
MediciNova is developing MN-166 for progressive MS and other
neurological conditions such as ALS and drug use disorders. MN-166
(ibudilast) is a first-in-class, orally bioavailable, small
molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a
macrophage migration inhibitory factor (MIF) inhibitor that
suppresses pro-inflammatory cytokines and promotes neurotrophic
factors. It attenuates activated glia cells, which play a major
role in certain neurological conditions. Ibudilast's
anti-neuroinflammatory and neuroprotective actions have been
demonstrated in preclinical and clinical study results and provide
the rationale for its therapeutic utility in neurodegenerative
diseases (e.g., progressive MS and amyotrophic lateral sclerosis
[ALS], also known as Lou Gehrig’s disease), substance
abuse/addiction and chronic neuropathic pain.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company
founded upon acquiring and developing novel, small-molecule
therapeutics for the treatment of diseases with unmet medical needs
with a primary commercial focus on the U.S. market. MediciNova's
current strategy is to focus on MN-166 (ibudilast) for neurological
disorders such as progressive MS, ALS and substance dependence
(e.g., methamphetamine dependence, opioid dependence) and MN-001
(tipelukast) for fibrotic diseases such as nonalcoholic
steatohepatitis (NASH) and idiopathic pulmonary fibrosis
(IPF). MediciNova’s pipeline also includes MN-221
(bedoradrine) for the treatment of acute exacerbations of asthma
and MN-029 (denibulin) for solid tumor cancers. MediciNova is
engaged in strategic partnering and other potential funding
discussions to support further development of its programs. For
more information on MediciNova, Inc., please visit
www.medicinova.com.
Statements in this press release that are not historical in
nature constitute forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements regarding the future development and
efficacy of MN-166, MN-221, MN-001, and MN-029. These
forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2016 and its subsequent periodic reports on
Forms 10-Q and 8-K. Undue reliance should not be placed on these
forward-looking statements, which speak only as of the date hereof.
MediciNova disclaims any intent or obligation to revise or update
these forward-looking statements.
INVESTOR CONTACT:
Geoff O'Brien
Vice President
MediciNova, Inc.
info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2023 to Sep 2024